CompletedNot Applicable

Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria

United States300 participantsStarted 2009-12

Plain-language summary

Carbapenems are a class of antibiotic agents which kill a broad spectrum of bacteria. Infections due to gram-negative bacteria which have acquired resistance to carbapenems are increasing, especially with Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa . The optimal treatment of such infections is not known. Antibiotics like polymyxin, tigecycline and rifampin are used alone or in combination with other antibiotics. The outcome of using these new and old drugs is not well studied. This observational study aims to study the clinical and microbiological outcomes of these infections and treatment at our institution.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adult in-patients (age≥18 years) having an infection due to CRGNB (Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa only). CRGNB Infection will be defined as isolation of CRGNB from any source requiring treatment with anti-infective agents with or without manifestations of systemic inflammatory response syndrome. Exclusion Criteria: * Patients colonized with CRGNB and not having an active infection. * Recurrent infection in a previously included patient.

What they're measuring

Clinical success

Timeframe: At the end of treatment

Trial details

NCT IDNCT01041716

SponsorMaimonides Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2010-12

View on ClinicalTrials.gov More Drug Resistance, Microbial trials